A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells

Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affected by mCRC with KRAS mutation or in the presence of constitutive activation of signalling pathways a...

Descripción completa

Detalles Bibliográficos
Autores principales: Landi, Nicola, Ciaramella, Vincenza, Ragucci, Sara, Chambery, Angela, Ciardiello, Fortunato, Pedone, Paolo V., Troiani, Teresa, Di Maro, Antimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867398/
https://www.ncbi.nlm.nih.gov/pubmed/36668877
http://dx.doi.org/10.3390/toxins15010057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867398/
https://www.ncbi.nlm.nih.gov/pubmed/36668877
http://dx.doi.org/10.3390/toxins15010057

Ejemplares similares